<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-title>Lipids in Health and Disease</journal-title><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-511X-8-12</article-id><article-id pub-id-type="pmid">19335919</article-id><article-id pub-id-type="doi">10.1186/1476-511X-8-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Paper</subject></subj-group></article-categories><title-group><article-title>Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>L&#x000f3;pez-Ruiz</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alru63@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Jarabo</surname><given-names>Mar&#x000ed;a M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jarabo_mar@gva.es</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Mart&#x000ed;nez-Triguero</surname><given-names>Mar&#x000ed;a L</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>martinez_mlutri@gva.es</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Morales-Su&#x000e1;rez-Varela</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>maria.m.morales@uv.es</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Sol&#x000e1;</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>sola_eva@gva.es</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Ba&#x000f1;uls</surname><given-names>Celia</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>Celia.Banuls@uv.es</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Casado</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>mcasado@ibv.csic.es</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Hern&#x000e1;ndez-Mijares</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>hernandez_antmij@gva.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Service of Endocrinology, University Hospital Dr Peset, Valencia, Spain</aff><aff id="I2"><label>2</label>Service of Clinical Analysis, University Hospital La Fe, Valencia, Spain</aff><aff id="I3"><label>3</label>CIBER CB/06/02/0045 research group, CIBER Actions in Epidemiology and Public Health, Valencia, Spain</aff><aff id="I4"><label>4</label>Medicine Department, University of Valencia, Valencia, Spain</aff><aff id="I5"><label>5</label>Institute of Biomedicina of Valencia (CSIC), CIBERehd, Valencia, Spain</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>31</day><month>3</month><year>2009</year></pub-date><volume>8</volume><fpage>12</fpage><lpage>12</lpage><ext-link ext-link-type="uri" xlink:href="http://www.lipidworld.com/content/8/1/12"/><history><date date-type="received"><day>12</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>31</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 L&#x000f3;pez-Ruiz et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>L&#x000f3;pez-Ruiz et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> L&#x000f3;pez-Ruiz Antonio alru63@hotmail.com </dc:author><dc:title> Small and dense LDL in familial combined hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Lipids in Health and Disease 8(1): 12-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-511X(2009)8:1&#x0003c;12&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-511X</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>There is a predominance of small and dense LDL cholesterol particles in familial combined hyperlipidemia (FCH). The lipoprotein lipase gene could exert an influence in these circumstances.</p><p>To study the relationship of pattern B LDL and lipids with N291S polymorphism of lipoprotein lipase (LPL) in FCH patients.</p><p>Lipid profile, apolipoproteins, diameter of LDL and N291S polymorphism were determined in 93 patients with FCH and 286 individuals from the general population.</p><p>FCH patients with N291S polymorphism showed a lower mean diameter of LDL. FCH patients with pattern B LDL showed higher concentrations of triglycerides, VLDLc, non-HDLc and apo B100 and lower levels of HDLc than those with pattern A. Of FCH patients with polymorphism 87.5% presented pattern B and 12.5% pattern A, while patients without polymorphism presented pattern A in 69.2% cases and pattern B in 30.8% cases, with differences being statistically significant (p &#x0003c; 0.004). The prevalence of this mutation in our FCH patients was 9.7%.</p><p>The prevalence of N291S mutation in our FCH patients was similar to the 9.3% described in Dutch FCHL patients but clearly higher than the 2&#x02013;5% described for other Caucasian populations. No polymorphism was found in our general population sample. FCH patients with phenotype B of LDL possessed an atherogenic lipid profile. The relationship between small and dense LDL and the presence of the N291S mutation may identify patients with high cardiovascular risk.</p></abstract></article-meta></front><body><sec><title>Background</title><p>A common form of dyslipemia associated with insulin resistance (obesity, diabetes mellitus, familial combined hyperlipidemia) is constituted by the presence of the atherogenic lipoprotein phenotype, characterized by elevated levels of triglycerides, small LDL particles and reduced HDL cholesterol [<xref ref-type="bibr" rid="B1">1</xref>]. This lipid triad frequently occurs in patients with premature coronary disease [<xref ref-type="bibr" rid="B2">2</xref>]. Small and dense LDL particles are formed largely as a response to high levels of triglycerides, and increase the risk of coronary heart disease [<xref ref-type="bibr" rid="B3">3</xref>]. LDL particles show a bimodal distribution in peak size and can be separated into two phenotypes; pattern A, in which larger, more buoyant LDL predominate, and pattern B, in which smaller, more dense LDL predominate. The National Cholesterol Education Program (ATP III) considers small and dense LDL as a lipid risk factor.</p><p>Familial Combined Hyperlipidemia (FCH; MIM 144250) is the most frequent genetic hyperlipemia. It is characterized by a tendency towards the appearance of coronary disease before 60 years of age [<xref ref-type="bibr" rid="B4">4</xref>]. The prevalence of this disease is 1&#x02013;2% in the general population [<xref ref-type="bibr" rid="B5">5</xref>] and 10&#x02013;20% among patients with premature coronary disease [<xref ref-type="bibr" rid="B6">6</xref>]. FCH presents a complex phenotype that is not completely understood, and which can vary between the patient and affected relatives [<xref ref-type="bibr" rid="B7">7</xref>]. Therefore, it is difficult to diagnose. It is also characterized by the presence of the atherogenic lipoprotein phenotype and an increase in apolipoprotein B100 [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Several genes have been studied in relation with FCH, which is a polygenic disease. One of the genes involved in FCH is lipoprotein lipase (LPL, E.C. 3.1.1.34) [<xref ref-type="bibr" rid="B9">9</xref>], a glycoproteic enzyme that plays a key role in the catabolism of lipoproteins rich in triglycerides, such as chylomicrons, and very low density lipoproteins (VLDL). LPL action takes place in endothelial cells surrounding the lumen of capillary vessels, where it adheres to heparan sulphate proteoglycans [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>More than 80 structural mutations have been detected within the LPL gene. The frequency of these mutations in the general population is estimated to be at least 1/500. These heterozygous mutations are the main cause of some lipid disorders. One of these mutations is N291S localized in exon 6 of LPL [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>].</p><p>The aim of our study was to analyze the relationship of the atherogenic lipoprotein profile, especially the predominance of small and dense LDL, with the prevalence of N291S LPL polymorphism in Spanish patients with FCH from the Community of Valencia with respect to with the general population.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Our study sample consisted of 33 families with Familial Combined Hyperlipidemia (FCH), with a mean of 4.4 individuals per family, all of them living in the Autonomous Community of Valencia (SE of Spain). From a total of 146 subjects, 93 were diagnosed with FCH according to the criteria of Bredie SJ et al. [<xref ref-type="bibr" rid="B14">14</xref>]. Total cholesterol and triglycerides levels superior to the 90<sup>th </sup>percentile (adjusted to age and gender) and apo B100 values superior to 1.2 g/L represented a diagnosis of FCH in 43 men and 50 women, aged from 15 to 75 years. In order to assess polymorphism in the general population, 286 genetically independent healthy controls of similar gender and age were randomly selected.</p><p>Venous blood was collected for biochemical measurements. Total cholesterol (TC) and triglycerides (TG) were measured through enzymatic methods and high density lipoproteins cholesterol (HDLc) using a direct method in a Beckman LX20 auto analyzer. The intraserial variation coefficient was &#x0003c; 3.5% for all these determinations. When TG values were under 400 mg/dL, LDL cholesterol concentration was calculated using Friedewald's formule [<xref ref-type="bibr" rid="B15">15</xref>]. Non-HDL cholesterol was obtained from the difference between total cholesterol and HDL cholesterol. Apolipoproteins AI and B100 were determined by immunonephelometry in a Dade Behring BNII (intra-assay variation coefficient &#x0003c; 5.5%).</p><p>LDL B phenotype was measured by polyacrylamide gradient gel electrophoresis (2&#x02013;16%) using the methodology described by Nichols et al. [<xref ref-type="bibr" rid="B16">16</xref>]. The assignment of LDL subclass phenotypes was based on particle diameter: pattern A, mean diameter &#x0003e; 25.5 nm, and pattern B, predominance of small and dense particles with a mean diameter &#x02264; 25.5 nm [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Approval was obtained from the relevant institutional review board, and all participants gave their informed consent.</p><sec><title>DNA analysis for RFLP detection in LPL</title><p>DNA was extracted from tubes of 15 mL of blood with EDTA-K<sub>3</sub>, according to the method of Miller et al. [<xref ref-type="bibr" rid="B18">18</xref>], and was conserved at 4&#x000b0;C until analysis was performed.</p><p>N291S was identified after PCR amplification of a 238 bp fragment using the following oligonucleotides: forward 5' GCCGAGATACAATCTTGGTG 3' and reverse 5' CTGCTTCTTTTGGCTCTGACTGT 3'. Such a polymorphism adds a restriction site for the Ava II enzyme. PCR reaction was performed in 25 &#x003bc;l total volume containing 0.3 mM of each primer, 0.2 mM of each dNTP, 1&#x000d7; Taq buffer, 2 mM MgCl<sub>2</sub>, 100 ng of genomic DNA and 2.5 U Taq polymerase (Netzyme) in a Master-Cycler thermocycler (Eppendorf). PCR was performed by means of a touchdown protocol [<xref ref-type="bibr" rid="B19">19</xref>] according to the following conditions: an initial denaturation step of 10 minutes at 94&#x000b0;C was followed by 4 cycles of 30 seconds at 94&#x000b0;C, 30 seconds at 60&#x000b0;C and 45 seconds at 72&#x000b0;C. This was followed by 20 cycles of 30 seconds at 94&#x000b0;C, 30 seconds at 60&#x000b0;C minus 0.5&#x000b0;C in each cycle and 45 seconds at 72&#x000b0;C, and then 10 cycles of 30 seconds at 94&#x000b0;C, 30 seconds at 50&#x000b0;C and 45 seconds at 72&#x000b0;C. The final extension consisted of 10 minutes at 72&#x000b0;C. The PCR product was digested for 4 hours at 37&#x000b0;C with Ava II and then analyzed with an 8% polyacrylamide gel. If the polymorphism was present, two fragments of 215 and 23 bp (HT+) appeared; if not, the site was destructed in the normal chain, which remained non-digested (238 bp: WT).</p></sec><sec><title>Study design</title><p>The study was conducted based on a case-control design. Ninety-three FCHL patients were recruited and matched according to sex and age with a control group of 286 subjects from the general population.</p></sec><sec><title>Statistics</title><p>Between-groups comparison was performed using an ANOVA followed by a parametric t-test. Due to skewed distribution of TG, TG analyses were performed on logarithmically transformed values. Statistical analyses were carried out using the Microsoft Excel Data Analysis Package (Microsoft, Inc.).</p><p>The Mann-Whitney nonparametric test was used to compare lipid concentrations in FCH patients with pattern A and those with pattern B. To test differences in triglycerides levels, values were logarithmically transformed prior to statistical analysis.</p><p>&#x003c7;<sup>2 </sup>was performed in order to determine whether populations were in Hardy-Weinberg equilibrium and in order to compare different phenotypes. Significance was set at p &#x0003c; 0.05.</p><p>Statistic analyses were carried out using the SSPS-15.0 program for Windows (SPSS Inc., Chicago, IL).</p></sec></sec><sec><title>Results</title><p>A total of 93 patients, all diagnosed with FCH, were studied: 43 men (46.3%) and 50 women (53.7%), aged between 15 and 75. 286 subjects from the general population were also studied. Lipid parameters are expressed in Table <xref ref-type="table" rid="T1">1</xref>. Significant differences were observed between the two groups in all the variables studied. FCH patients showed higher levels of total cholesterol, triglycerides, LDLc, non-HDLc and apo B100, and lower levels of HDLc, apo A and a smaller LDL diameter.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Lipid concentrations in cases (FCH patients) and controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">FCH Patients</td><td align="center">Controls</td><td align="center">P value*</td></tr></thead><tbody><tr><td align="left">Total cholesterol</td><td align="center">238.67 &#x000b1; 50.10</td><td align="center">185.13 &#x000b1; 28.30</td><td align="center">0.001</td></tr><tr><td align="left">Triglycerides</td><td align="center">204.71 &#x000b1; 192.16</td><td align="center">88.27 &#x000b1; 42.45</td><td align="center">0.001</td></tr><tr><td align="left">LDLc</td><td align="center">156.85 &#x000b1; 39.97</td><td align="center">113.50 &#x000b1; 25.20</td><td align="center">0.001</td></tr><tr><td align="left">HDLc</td><td align="center">47.77 &#x000b1; 17.18</td><td align="center">53.93 &#x000b1; 14.48</td><td align="center">0.001</td></tr><tr><td align="left">VLDLc</td><td align="center">40.28 &#x000b1; 36.52</td><td align="center">17.65 &#x000b1; 8.49</td><td align="center">0.001</td></tr><tr><td align="left">Non-HDLc</td><td align="center">192.94 &#x000b1; 48.68</td><td align="center">131.50 &#x000b1; 29.09</td><td align="center">0.001</td></tr><tr><td align="left">Apo AI</td><td align="center">133.55 &#x000b1; 32.52</td><td align="center">152.79 &#x000b1; 29.03</td><td align="center">0.001</td></tr><tr><td align="left">Apo B100</td><td align="center">125.80 &#x000b1; 28.11</td><td align="center">95.25 &#x000b1; 21.15</td><td align="center">0.001</td></tr><tr><td align="left">LDL diameter</td><td align="center">25.45 &#x000b1; 0.78</td><td align="center">26.14 &#x000b1; 0.74</td><td align="center">0.001</td></tr></tbody></table><table-wrap-foot><p>* ANOVA Test</p><p>Values are expressed as mean &#x000b1; standard deviation. Units are mg/dL in all parameters except LDL diameter (nm).</p></table-wrap-foot></table-wrap><p>When non-mutated wild-type (WT) and heterozygote (HT) patients were compared, a smaller average diameter of LDL particles was observed among the latter, with the difference being statistically significant. Table <xref ref-type="table" rid="T2">2</xref> shows the lipid values of pattern A patients compared to those of pattern B patients. FCH patients with pattern B LDL displayed higher concentrations of triglycerides, VLDLc, non-HDLc and apo B100 and lower levels of HDLc than FCH patients with pattern A.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Lipid concentrations in FCH patients with pattern A and pattern B</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Pattern A (n = 26)</td><td align="center">Pattern B (n = 27)</td><td align="center">P-value*</td></tr></thead><tbody><tr><td align="left">Total cholesterol</td><td align="center">227.88 &#x000b1; 41.86</td><td align="center">238.03 &#x000b1; 50.86</td><td align="center">0.450</td></tr><tr><td align="left">Triglycerides</td><td align="center">127.80 &#x000b1; 65.77</td><td align="center">344.55 &#x000b1; 234.40</td><td align="center">0.001</td></tr><tr><td align="left">HDLc</td><td align="center">55.00 &#x000b1; 18.54</td><td align="center">35.59 &#x000b1; 7.94</td><td align="center">0.001</td></tr><tr><td align="left">LDLc</td><td align="center">147.50 &#x000b1; 34.64</td><td align="center">149.06 &#x000b1; 53.11</td><td align="center">0.569</td></tr><tr><td align="left">VLDLc</td><td align="center">25.53 &#x000b1; 13.11</td><td align="center">65.34 &#x000b1; 43.71</td><td align="center">0.001</td></tr><tr><td align="left">Non-HDLc</td><td align="center">172.88 &#x000b1; 32.40</td><td align="center">202.44 &#x000b1; 50.71</td><td align="center">0.022</td></tr><tr><td align="left">Apo AI</td><td align="center">144.00 &#x000b1; 39.87</td><td align="center">121.33 &#x000b1; 20.49</td><td align="center">0.029</td></tr><tr><td align="left">Apo B100</td><td align="center">118.13 &#x000b1; 22.22</td><td align="center">133.69 &#x000b1; 30.21</td><td align="center">0.042</td></tr><tr><td align="left">ApoB/ApoA</td><td align="center">0.90 &#x000b1; 0.29</td><td align="center">1.50 &#x000b1; 0.35</td><td align="center">0.022</td></tr><tr><td align="left">Diameter</td><td align="center">26.06 &#x000b1; 0.57</td><td align="center">24.86 &#x000b1; 0.42</td><td align="center">0.001</td></tr></tbody></table><table-wrap-foot><p>* Mann-Whitney test</p><p>Values expressed as mean &#x000b1; Standard Deviation. Units are mg/dL in all parameters</p></table-wrap-foot></table-wrap><p>Patients with polymorphism presented pattern B in 87.5% of cases and pattern A in 12.5% of cases, while patients without polymorphism presented pattern A in 69.2% of cases and pattern B in 30.8% of cases. These differences were statistically significant (p &#x0003c; 0.004).</p><p>N291S polymorphism of LPL occurred in 9.7% of FCH patients, while no individual in the study sample from the general population presented this mutation. Both samples were in Hardy-Weinberg equilibrium, as the patients showed a &#x003c7;<sup>2 </sup>= 0.216 and 2p = 0.6423 and the general population a &#x003c7;<sup>2 </sup>= 0 and 2p = 1.</p></sec><sec><title>Discussion</title><p>FCH is a disease with a complex phenotype that is not completely understood, and remains difficult to diagnose. This dyslipemic syndrome is associated with disturbances in all lipoprotein fractions. The key underlying abnormality of this condition is elevation of VLDL due to overproduction or defective catabolism [<xref ref-type="bibr" rid="B20">20</xref>]. Small and dense LDL is the final expression of this catabolism. These particles are more easily oxidized and display a higher affinity for the extracellular matrix and a higher degree of retention in arterial wall than their larger, normal-sized counterparts [<xref ref-type="bibr" rid="B21">21</xref>]. Small and dense LDL has been accepted as an emergent cardiovascular risk factor by the National Cholesterol Education Programme (Adult Treatment Panel III) [<xref ref-type="bibr" rid="B22">22</xref>], as many studies have demonstrated that the predominance of these particles is associated with an increase in cardiovascular risk more than classic lipid variables [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. FCH patients with phenotype B of LDL show a clearly atherogenic lipid profile. There is evidence that hypolipidemic treatment can modify the distribution of LDL subclasses [<xref ref-type="bibr" rid="B25">25</xref>]. Very high risk patients, including those with this atherogenic lipoprotein profile, may benefit from more potent lipid-lowering therapies [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>It has been suggested that FCH is a heterogeneous and oligogenic disease [<xref ref-type="bibr" rid="B27">27</xref>]. One of the genes likely to exert an influence in this disease is the lipoprotein lipase gene. Many codon polymorphisms of the LPL gene have been described, some of them associated with alterations of the metabolism of triglyceride-rich lipoproteins [<xref ref-type="bibr" rid="B28">28</xref>]. One of the most frequent polymorphisms is located in exon 6 (rs268, c. 1128 A&#x0003e;G; N291S) [<xref ref-type="bibr" rid="B29">29</xref>]. The prevalence of this mutation in our FCH patients was 9.7%, which is similar to the 9.3% described for Dutch FCH patients [<xref ref-type="bibr" rid="B5">5</xref>] but considerably higher than the 2&#x02013;5% described for other Caucasian populations [<xref ref-type="bibr" rid="B30">30</xref>]. No polymorphism was detected in the sample from the general population, which reflects findings in other populations [<xref ref-type="bibr" rid="B5">5</xref>] in which no carriers were found, suggesting that the N291S mutation is more frequent among FCH patients. The mutation is likely to affect postprandial lipemia by altering its enzymatic activity [<xref ref-type="bibr" rid="B31">31</xref>], resulting in an increase of VLDL particles and high concentrations of apo B100 and leading to the appearance of a greater number of small and dense LDL particles as the final and most important expression of the catabolism of triglyceride-rich lipoprotein particles [<xref ref-type="bibr" rid="B32">32</xref>]. In this way, the FCH phenotype of patients with the polymorphism is negatively affected, with altered postprandial responses to fat-rich meals being described, even in patients that were initially normolipemic [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>These previously published data coincide with our results; polymorphism-carrier patients have been reported to present a smaller LDL diameter, suggesting a clearly atherogenic alteration of the metabolism of triglyceride-rich particles [<xref ref-type="bibr" rid="B34">34</xref>]. In fact, in some studies regarding FCH, this polymorphism has been related to patients who had previously presented an ischemic cardiopathy [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>In our study, patients with the N291S polymorphism showed a smaller average LDL diameter, corresponding with pattern B and constituting the final expression of the alteration of the metabolism of triglyceride-rich particles. This represents a higher cardiovascular risk among such patients. On the other hand, most patients without this polymorphism had pattern A, constituting a clear difference between both groups. We are aware of the limitations of this study in relation to the number of patients with the polymorphism. Unfortunately, its low prevalence among the general population makes it difficult to conduct a genetic study with a large number of patients that would permit us to draw more solid conclusions. That said, our data show important differences between the two patterns.</p><p>In conclusion, FCH patients with pattern B of LDL show a clearly atherogenic lipid profile. The relationship between small and dense LDL and the presence of the allele encoding for N291S mutation of the LPL gene, present in a high percentage of our FCH patients, could disrupt the phenotype of the disease by altering the clearance of triglyceride-rich lipoproteins. Such phenotype expression is the basis for a more atherogenic profile. Therefore, based on our results in FCH patients in the Autonomous Community of Valencia, the cardiovascular risk of those with pattern B of LDL who carry this polymorphism could be considerably reduced through rigorous treatment of Hyperlipemia.</p></sec><sec><title>Abbreviations</title><p>FCH: Familial combined hypermipidemia; LPL: lipoprotein lipase; WT: non-mutated wil-type; HT: Heterzygote.</p></sec><sec><title>Competing interests</title><p>The authours declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>AH-M, AL-R and MM-T participated in the design of the study, MJ, AL-R and MM-T carried out the laboratory studies. CB and MM performed the statistical analysis and interpretation of data. MC and AL-R carried out the molecular genetic studies. ES and AH-M have been involved in the revision of the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Acknowledgements</title><p>MC was supported by grant SAF2006-06760 from CICYT, Spain and by a grant from Instituto de Salud Carlos III (Red de Centros FIS-RECAVA RD06/0014/0025).</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name></person-group><article-title>Hypertriglyceridemia, atherogenic dyslipidemia and the metabolic syndrome</article-title><source>Am J Cardiol</source><year>1998</year><volume>81</volume><fpage>18B</fpage><lpage>25B</lpage><pub-id pub-id-type="pmid">9526809</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>MA</given-names></name><name><surname>King</surname><given-names>MC</given-names></name><name><surname>Vranizan</surname><given-names>KM</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name></person-group><article-title>Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk</article-title><source>Circulation</source><year>1990</year><volume>82</volume><fpage>495</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">2372896</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St-Pierre</surname><given-names>AC</given-names></name><name><surname>Cantin</surname><given-names>B</given-names></name><name><surname>Dagenais</surname><given-names>GR</given-names></name><name><surname>Mauri&#x000e8;ge</surname><given-names>P</given-names></name><name><surname>Bernard</surname><given-names>PM</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><name><surname>Lamarche</surname><given-names>B</given-names></name></person-group><article-title>Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">15618542</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eurlings</surname><given-names>PM</given-names></name><name><surname>Kallen</surname><given-names>CJ van der</given-names></name><name><surname>Geurts</surname><given-names>JM</given-names></name><name><surname>van Greevenbroek</surname><given-names>MM</given-names></name><name><surname>de Bruin</surname><given-names>TW</given-names></name></person-group><article-title>Genetic dissection of familial combined hyperlipidemia</article-title><source>Mol Genet Metab</source><year>2001</year><volume>74</volume><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">11592807</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffer</surname><given-names>MJV</given-names></name><name><surname>Bredie</surname><given-names>SJH</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Reymer</surname><given-names>PWA</given-names></name><name><surname>Kastelein</surname><given-names>JJP</given-names></name><name><surname>de Knijff</surname><given-names>P</given-names></name><name><surname>Demacker</surname><given-names>PNM</given-names></name><name><surname>Stalenhoef</surname><given-names>AFH</given-names></name><name><surname>Havekes</surname><given-names>LM</given-names></name><name><surname>Frants</surname><given-names>RR</given-names></name></person-group><article-title>The lipoprotein lipase (Asn291-Ser) mutation associated with elevated lipid level families with familial combined hyperlipidaemia</article-title><source>Atherosclerosis</source><year>1996</year><volume>119</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">8808493</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Schrott</surname><given-names>HG</given-names></name><name><surname>Hazzard</surname><given-names>WR</given-names></name><name><surname>Bierman</surname><given-names>EL</given-names></name><name><surname>Motulsky</surname><given-names>AG</given-names></name></person-group><article-title>Hyperlipidemia in coronary heart disease II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia</article-title><source>J Clin Invest</source><year>1973</year><volume>52</volume><fpage>1544</fpage><lpage>1568</lpage><pub-id pub-id-type="pmid">4718953</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porkka</surname><given-names>KV</given-names></name><name><surname>Nuotio</surname><given-names>I</given-names></name><name><surname>Pajukanta</surname><given-names>P</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Suurinkeroinen</surname><given-names>L</given-names></name><name><surname>Syv&#x000e4;nne</surname><given-names>M</given-names></name><name><surname>Lehtim&#x000e4;ki</surname><given-names>T</given-names></name><name><surname>Lahdenkari</surname><given-names>AT</given-names></name><name><surname>Lahdenper&#x000e4;</surname><given-names>S</given-names></name><name><surname>Ylitalo</surname><given-names>K</given-names></name><name><surname>Antikainen</surname><given-names>M</given-names></name><name><surname>Perola</surname><given-names>M</given-names></name><name><surname>Raitakari</surname><given-names>OT</given-names></name><name><surname>Kovanen</surname><given-names>P</given-names></name><name><surname>Viikari</surname><given-names>JS</given-names></name><name><surname>Peltonen</surname><given-names>L</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name></person-group><article-title>Phenotype expression in familial combined hyperlipidemia</article-title><source>Atherosclerosis</source><year>1997</year><volume>133</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">9298685</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ayyobi</surname><given-names>AF</given-names></name><name><surname>McGladdery</surname><given-names>SH</given-names></name><name><surname>McNeely</surname><given-names>MJ</given-names></name><name><surname>Austin</surname><given-names>MA</given-names></name><name><surname>Motulsky</surname><given-names>AG</given-names></name><name><surname>Brunzell</surname><given-names>JD</given-names></name></person-group><article-title>Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><fpage>1289</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">12750118</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases</article-title><source>J Lipid Res</source><year>2006</year><volume>47</volume><fpage>1908</fpage><lpage>1914</lpage><pub-id pub-id-type="pmid">16741292</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Enerback</surname><given-names>S</given-names></name><name><surname>Gimble</surname><given-names>JM</given-names></name></person-group><article-title>Lipoprotein lipase gene expression: physiological regulator at the transcriptional and post-transcriptional level</article-title><source>Biochem Biophys Acta</source><year>1993</year><volume>1169</volume><fpage>107</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">8343535</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerdes</surname><given-names>C</given-names></name><name><surname>Fisher</surname><given-names>RM</given-names></name><name><surname>Nicaud</surname><given-names>V</given-names></name><name><surname>Boer</surname><given-names>J</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Talmud</surname><given-names>PJ</given-names></name><name><surname>Faergeman</surname><given-names>O</given-names></name></person-group><article-title>Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>733</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">9264476</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wittrup</surname><given-names>HH</given-names></name><name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name><name><surname>Abildgaard</surname><given-names>S</given-names></name><name><surname>Steffensen</surname><given-names>R</given-names></name><name><surname>Schnohr</surname><given-names>P</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name></person-group><article-title>A common substitution (Asn291Ser) in Lipoprotein Lipase is associated with increased risk of ischemic heart disease</article-title><source>J Clin Invest</source><year>1997</year><volume>99</volume><fpage>1606</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">9120004</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reymer</surname><given-names>PW</given-names></name><name><surname>Groenemeyer</surname><given-names>BE</given-names></name><name><surname>Gagn&#x000e9;</surname><given-names>E</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Appelman</surname><given-names>EE</given-names></name><name><surname>Seidel</surname><given-names>JC</given-names></name><name><surname>Kromhout</surname><given-names>D</given-names></name><name><surname>Bijvoet</surname><given-names>SM</given-names></name><name><surname>Oever</surname><given-names>K van de</given-names></name><name><surname>Bruin</surname><given-names>T</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Kastelein</surname><given-names>JJP</given-names></name></person-group><article-title>A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia</article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><fpage>1543</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">8541837</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bredie</surname><given-names>SJ</given-names></name><name><surname>Demacker</surname><given-names>PN</given-names></name><name><surname>Stalenhoef</surname><given-names>AF</given-names></name></person-group><article-title>Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity</article-title><source>Eur J Clin Invest</source><year>1997</year><volume>27</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">9373757</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedewald</surname><given-names>WT</given-names></name><name><surname>Levy</surname><given-names>RI</given-names></name><name><surname>Fredrickson</surname><given-names>DS</given-names></name></person-group><article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge</article-title><source>Clin Chem</source><year>1972</year><volume>18</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>AV</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Musliner</surname><given-names>TA</given-names></name></person-group><article-title>Nondenaturing polyacrylamide gradient gel electrophoresis</article-title><source>Methods Enzymol</source><year>1986</year><volume>128</volume><fpage>417</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">3724517</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>MA</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Brunzell</surname><given-names>JD</given-names></name></person-group><article-title>Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance</article-title><source>Curr Opin Lipidol</source><year>1994</year><volume>5</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">7712044</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SA</given-names></name><name><surname>Dykes</surname><given-names>DD</given-names></name><name><surname>Polesky</surname><given-names>HF</given-names></name></person-group><article-title>A simple salting out procedure for extracting DNA from human nucleated cells</article-title><source>Nucleic Acids Res</source><year>1988</year><volume>16</volume><fpage>1215</fpage><pub-id pub-id-type="pmid">3344216</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hecker</surname><given-names>KH</given-names></name><name><surname>Roux</surname><given-names>KH</given-names></name></person-group><article-title>High and low annealing temperatures increase both specificity and yield in touchdown and step-down PCR</article-title><source>Biotechniques</source><year>1996</year><volume>20</volume><fpage>478</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">8679209</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adiels</surname><given-names>M</given-names></name><name><surname>Olofsson</surname><given-names>SO</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Bor&#x000e9;n</surname><given-names>J</given-names></name></person-group><article-title>Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><fpage>1225</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">18565848</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Packard</surname><given-names>CJ</given-names></name></person-group><article-title>Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease</article-title><source>Curr Opin Lipidol</source><year>2006</year><volume>17</volume><fpage>412</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">16832165</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajman</surname><given-names>I</given-names></name><name><surname>Eacho</surname><given-names>PI</given-names></name><name><surname>Chowienczyk</surname><given-names>PJ</given-names></name><name><surname>Ritter</surname><given-names>JM</given-names></name></person-group><article-title>LDL particle size: an important drug target?</article-title><source>Br J Clin Pharmacol</source><year>1999</year><volume>48</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">10417486</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Merz</surname><given-names>CN</given-names></name><name><surname>Brewer</surname><given-names>HB</given-names><suffix>Jr</suffix></name><name><surname>Clark</surname><given-names>LT</given-names></name><name><surname>Hunninghake</surname><given-names>DB</given-names></name><name><surname>Pasternak</surname><given-names>RC</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Stone</surname><given-names>NJ</given-names></name><collab>National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association</collab></person-group><article-title>Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines</article-title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">15249516</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarvik</surname><given-names>GP</given-names></name><name><surname>Brunzell</surname><given-names>JD</given-names></name><name><surname>Austin</surname><given-names>MA</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Motulsky</surname><given-names>AG</given-names></name><name><surname>Wijsman</surname><given-names>E</given-names></name></person-group><article-title>Genetic predictors of FCH in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype</article-title><source>Arterioscler Thromb</source><year>1994</year><volume>14</volume><fpage>1687</fpage><lpage>1694</lpage><pub-id pub-id-type="pmid">7947591</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nevin</surname><given-names>DN</given-names></name><name><surname>Brunzell</surname><given-names>JD</given-names></name><name><surname>Deeb</surname><given-names>SS</given-names></name></person-group><article-title>The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity</article-title><source>Arterioscler Thromb</source><year>1994</year><volume>14</volume><fpage>869</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">8199176</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Bockxmeer</surname><given-names>FM</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Mamotte</surname><given-names>C</given-names></name><name><surname>Burke</surname><given-names>U</given-names></name><name><surname>Taylor</surname><given-names>R</given-names></name></person-group><article-title>Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids</article-title><source>Atherosclerosis</source><year>2001</year><volume>157</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">11427211</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wittekoek</surname><given-names>ME</given-names></name><name><surname>Pimstone</surname><given-names>SN</given-names></name><name><surname>Reymer</surname><given-names>PW</given-names></name><name><surname>Feuth</surname><given-names>L</given-names></name><name><surname>Botma</surname><given-names>GJ</given-names></name><name><surname>Defesche</surname><given-names>JC</given-names></name><name><surname>Prins</surname><given-names>M</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name></person-group><article-title>A common mutation in the lipoprotein lipase (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia</article-title><source>Circulation</source><year>1998</year><volume>97</volume><fpage>729</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">9498535</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Razzaghi</surname><given-names>H</given-names></name><name><surname>Day</surname><given-names>BW</given-names></name><name><surname>McClure</surname><given-names>RJ</given-names></name><name><surname>Kamboh</surname><given-names>MI</given-names></name></person-group><article-title>Structure-function analysis of D9N and N291S mutations in human lipoprotein lipase using molecular modelling</article-title><source>J Mol Graph Model</source><year>2001</year><volume>19</volume><comment>487&#x02013;494, 587&#x02013;590.</comment><pub-id pub-id-type="pmid">11552677</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Georgieva</surname><given-names>AM</given-names></name><name><surname>van Greevenbroek</surname><given-names>MM</given-names></name><name><surname>Krauss</surname><given-names>RM</given-names></name><name><surname>Brouwers</surname><given-names>MC</given-names></name><name><surname>Vermeulen</surname><given-names>VM</given-names></name><name><surname>Robertus-Teunissen</surname><given-names>MG</given-names></name><name><surname>Kallen</surname><given-names>CJ van der</given-names></name><name><surname>de Bruin</surname><given-names>TW</given-names></name></person-group><article-title>Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2004</year><volume>24</volume><fpage>744</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">14751815</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pimstone</surname><given-names>SN</given-names></name><name><surname>Clee</surname><given-names>SM</given-names></name><name><surname>Gagne</surname><given-names>SE</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Stein</surname><given-names>EA</given-names></name><name><surname>Hayden</surname><given-names>MR</given-names></name></person-group><article-title>A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers</article-title><source>J Lipid Res</source><year>1996</year><volume>37</volume><fpage>1675</fpage><lpage>1684</lpage><pub-id pub-id-type="pmid">8864951</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>PN</given-names></name><name><surname>Heiss</surname><given-names>G</given-names></name><name><surname>Ellison</surname><given-names>RC</given-names></name><name><surname>Province</surname><given-names>MA</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Eckfeldt</surname><given-names>JH</given-names></name><name><surname>Hunt</surname><given-names>SC</given-names></name></person-group><article-title>Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study</article-title><source>Circulation</source><year>2003</year><volume>108</volume><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">12847072</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><collab>National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III)</collab></person-group><article-title>Third Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) final report</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>3143</fpage><lpage>3421</lpage><pub-id pub-id-type="pmid">12485966</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vakkilainen</surname><given-names>J</given-names></name><name><surname>Steiner</surname><given-names>G</given-names></name><name><surname>Ansquer</surname><given-names>JC</given-names></name><name><surname>Aubin</surname><given-names>F</given-names></name><name><surname>Rattier</surname><given-names>S</given-names></name><name><surname>Foucher</surname><given-names>Ch</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>DAIS</surname><given-names>Group</given-names></name></person-group><article-title>Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>1733</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">12665498</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hurt-Camejo</surname><given-names>E</given-names></name><name><surname>Camejo</surname><given-names>G</given-names></name><name><surname>Sartipy</surname><given-names>P</given-names></name></person-group><article-title>Phospholipase A2 and small, dense low-density lipoprotein</article-title><source>Curr Opin Lipidol</source><year>2000</year><volume>11</volume><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">11048889</pub-id></citation></ref></ref-list></back></article> 